United Kingdom

People: Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

8:37pm BST
Change (% chg)

$-0.14 (-2.32%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lawlor, Augustine 

Mr. Augustine J. Lawlor is re designated as Chairman of the Board of the company effective February 15, 2018. He has been a managing director of HealthCare Ventures since 2000. From 1997 to 2000, he served as chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV and V company. Prior to joining LeukoSite, Mr. Lawlor was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He has held similar positions at both BioSurface Technology and Armstrong Pharmaceuticals. Mr. Lawlor was previously a management consultant with KPMG Peat Marwick. Mr. Lawlor has been a member of the board of directors of Catalyst since February 2006. He is currently a director of Cardiovascular Systems, Globe Immune, Promedior, Inc., Mosaic Biosciences, Inc., Tensha Therapeutics, Inc., HealthCare Pharmaceuticals, Inc., Cleveland HeartLab, LLC, GITR, Inc., Anexon, Inc. and the Slater Center for Biomedical Technology, a technology commercialization center providing support services for development of therapeutics. Mr. Lawlor has previously served as a director of uman Genome Sciences, which was acquired by GlaxoSmithKline and Replidyne, Inc. Mr. Lawlor received his Master’s in Public and Private Management from Yale University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --